Regeneron Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Regeneron Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $53 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $59 tied up three years earlier. More money tied up than 95% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times. Higher than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$109Over the last 3 years, every $100 of reported profit came with $109 of operating cash.
Lower than 79% of Healthcare companies in United States.
Self-Funding Ratio
4.6×Over the last 3 years its own operating cash covered its investment spending (capex) 4.6 times.
Higher than 85% of Healthcare companies in United States.
Cash Locked Ratio
$53For every $100 of sales, $53 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $59 tied up three years earlier.
More money tied up than 95% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$8Sales grew 18% in 3 years; of every extra $100 of sales, $8 became extra profit.
Lower than 59% of Healthcare companies in United States.
Asset Productivity Ratio
+18% / +39%In 3 years sales changed by +18% while total assets changed by +39%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Lower than 54% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 79% of Healthcare companies in United States.
Tangible Net Worth Ratio
96%Of every $100 of net worth, $96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 83% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Regeneron Pharmaceuticals, Inc. owes $0.24 for every $1 it owns. Net profit rose 2% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
20.3Investors pay $20.3 for every $1 of Regeneron Pharmaceuticals, Inc.'s yearly profit, lower than 64% of Healthcare companies in United States.
P/B ratio
2.66The share price is 2.66 times Regeneron Pharmaceuticals, Inc.'s book value per share, higher than 51% of Healthcare companies in United States.
Market cap
$84.3 BThe total market value of all of Regeneron Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 98% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$31.7 BWhat Regeneron Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$308.01Net worth divided by the number of shares. The share price of $819.09 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
14.0%Regeneron Pharmaceuticals, Inc. earned 14.0% on its shareholders' money over the last year, higher than 86% of Healthcare companies in United States.
Owes vs Owns
0.24×Regeneron Pharmaceuticals, Inc. owes $0.24 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Dividend yield
0.47%Regeneron Pharmaceuticals, Inc. pays 0.47% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in United States.
Revenue growth
+1%Revenue rose 1% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Profit growth
+2%Net profit rose 2% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Profit margin
31.4%Regeneron Pharmaceuticals, Inc. keeps $31 of every $100 of revenue as net profit.
Cash quality
1.1×Cash from Regeneron Pharmaceuticals, Inc.'s business was 1.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
84.5×Regeneron Pharmaceuticals, Inc.'s operating profit covered its interest costs 84.5 times in the year to Dec 2025.
Cash vs debt
Net cashRegeneron Pharmaceuticals, Inc. held $5.9 B more cash than debt (net cash) at Dec 2025.
Questions
What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $20.3 for every $1 of Regeneron Pharmaceuticals, Inc.'s yearly profit, lower than 64% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Regeneron Pharmaceuticals, Inc.: $84.3 B ÷ $31.7 B (30 Jun 2026) = 2.7.
What is Regeneron Pharmaceuticals, Inc.'s return on equity?
Regeneron Pharmaceuticals, Inc. earned 14.0% on its shareholders' money over the last year, higher than 86% of Healthcare companies in United States.
How much does Regeneron Pharmaceuticals, Inc. owe compared with what it owns?
Regeneron Pharmaceuticals, Inc. owes $0.24 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes. Regeneron Pharmaceuticals, Inc. pays 0.47% of its share price as dividends a year, lower than 80% of dividend-paying Healthcare companies in United States.
Is Regeneron Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 1% in the year to Dec 2025, and grew 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.